MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Oxaliplatin resistance limits the efficiency of treatment for colorectal cancer (CRC). Studies have shown that abnormal expression of microRNAs (miRNAs) were associated with tumorigenesis, cancer development and chemoresistance. The purpose of this study was to identify potential miRNAs related to oxaliplatin resistance in CRC cells. In this work, using small RNA sequencing (small RNA-Seq) and transcriptome sequencing (RNA-Seq), we found that down-regulated miR-483-3p was concurrent with up-regulated FAM171B in oxaliplatin-resistant colorectal cancer cell line HCT116/L as compared with its parental cell line HCT116. Transient transfection of miR-483-3p mimics markedly decreased the levels of FAM171B and restored oxaliplatin responsiveness of HCT116/L cells, and this alteration enhanced cell apoptosis and weakened cell migration. Whereas miR-483-3p inhibitor dramatically promoted the expression of FAM171B and enhanced oxaliplatin resistance of HCT116 cells by repressing cell apoptosis. Furthermore, knockdown of FAM171B in HCT116/L cells could also sensitize its reaction of the treatment with oxaliplatin, which was verified by the reduced cell migration. These findings demonstrate that FAM171B is a functional target of miR-483-3p in the regulation of oxaliplatin resistance in human CRC cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the other hand, miR-483-3p is downregulated in oxaliplatin-resistant CRC cells, and miR-483-3p mimics restored oxaliplatin responsiveness via increased apoptosis [179].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [179]
Citations
Cites
Differential expression analysis for sequence count data
Anders, S., & Huber, W. (2010) · Genome Biology · doi:10.1186/gb-2010-11-10-r106 · Cited by 15,581
Fast and effective prediction of microRNA/target duplexes
REHMSMEIER, M., STEFFEN, P., HÖCHSMANN, M., & GIEGERICH, R. (2004) · RNA · doi:10.1261/rna.5248604 · Cited by 2,560
The microRNA.org resource: targets and expression
Betel, D., Wilson, M., Gabow, A., Marks, D. S., & Sander, C. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm995 · Cited by 2,503
Fahlgren, N., Howell, M. D., Kasschau, K. D., Chapman, E. J., Sullivan, C. M., Cumbie, J. S., Givan, S. A., Law, T. F., Grant, S. R., Dangl, J. L., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000219 · Cited by 1,197
Getting to the Root of miRNA-Mediated Gene Silencing
Eulalio, A., Huntzinger, E., & Izaurralde, E. (2008) · Cell · doi:10.1016/j.cell.2007.12.024 · Cited by 1,079
Yang, H., Kong, W., He, L., Zhao, J.-J., O'Donnell, J. D., Wang, J., Wenham, R. M., Coppola, D., Kruk, P. A., Nicosia, S. V., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2488 · Cited by 1,051
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Zhou, Y., Tozzi, F., Chen, J., Fan, F., Xia, L., Wang, J., Gao, G., Zhang, A., Xia, X., Brasher, H., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1674 · Cited by 374
Romualdi, C., Bortoluzzi, S., d’Alessi, F., & Danieli, G. A. (2003) · Physiological Genomics · doi:10.1152/physiolgenomics.00096.2002 · Cited by 352
Valeri, N., Braconi, C., Gasparini, P., Murgia, C., Lampis, A., Paulus-Hock, V., Hart, J. R., Ueno, L., Grivennikov, S. I., Lovat, F., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.006 · Cited by 286
Graham, J., Muhsin, M., & Kirkpatrick, P. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1287 · Cited by 251
Cited by
Role of non-coding RNAs and RNA modifiers in cancer therapy resistance
Zhang, X., Xie, K., Zhou, H., Wu, Y., Li, C., Liu, Y., Liu, Z., Xu, Q., Liu, S., Xiao, D., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01171-z · Cited by 237
Jeong, S., Kim, B. G., Kim, D. Y., Kim, B. R., Kim, J. L., Park, S. H., Na, Y. J., Jo, M. J., Yun, H. K., Jeong, Y. A., et al. (2019) · Cancers · doi:10.3390/cancers11060781 · Cited by 98
Drug resistance in colorectal cancer: An epigenetic overview
Luo, M., Yang, X., Chen, H.-N., Nice, E. C., & Huang, C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188623 · Cited by 94
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“On the other hand, miR-483-3p is downregulated in oxaliplatin-resistant CRC cells, and miR-483-3p mimics restored oxali-platin responsiveness via increased apoptosis [179].”
Advanced technological tools to study multidrug resistance in cancer
Andrei, L., Kasas, S., Ochoa, I., Stanković, T., Korsnes, M. S., Václavíková, R., Assaraf, Y. G., & Pešić, M. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100658 · Cited by 74
Metadata
- Authors
- Liang, H., Xu, Y., Zhang, Q., Yang, Y., Mou, Y., Gao, Y., Chen, R., Chen, C., & Dai, P.
- Affiliations
- Northwest University (US)
- National Engineering Research Center for Miniaturized Detection Systems, School of Life Sciences, Northwest University
- Corresponding author
- Dai, Penggao
- Venue
- Artificial Cells, Nanomedicine, and Biotechnology
- Publisher
- Informa UK Limited
- Published
- 2019-03-12
- Volume
- 47
- Issue
- 1
- Pages
- 725-736
- ISSN
- 2169-1401 (ISSN-L)
- 2169-141X
- OpenAlex
- W2921842373
- Cited by
- 43
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 1 · 2023: 7 · 2022: 2 · 2021: 12 · 2020: 8 · 2019: 5
- FWCI
- 2.13
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- doi.org/10.1080/policies-text-data-mining (tdm)
- Locations
- Artificial Cells Nanomedicine and Biotechnology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Shaanxi Natural Science Foundation (2018JZ3007)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- miR-483-3p, oxaliplatin resistance, colorectal cancer, chemoresistance, microRNA target regulation, apoptosis, cell migration
- MeSH terms
- Oxaliplatin, Antineoplastic Agents, Cell Movement, Humans, Membrane Proteins, Neoplasm Proteins, Colorectal Neoplasms, Gene Expression, Gene Expression Regulation, Neoplastic, Apoptosis, Drug Resistance, Neoplasm, Gene Expression Profiling, MicroRNAs, HCT116 Cells, Cell Line, Tumor, Cell Proliferation, Gene Knockdown Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells. https://app.cochat.ai/papers/10.1080/21691401.2019.1569530
- The paper
- Liang, H., Xu, Y., Zhang, Q., Yang, Y., Mou, Y., Gao, Y., Chen, R., Chen, C., & Dai, P. (2019). MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells. Artificial Cells, Nanomedicine, and Biotechnology. https://doi.org/10.1080/21691401.2019.1569530
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.